Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07409246 | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 | 127 | AbbVieINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT04722146 | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MajesTEC-2) | active not recruiting | Phase 1 | 140 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 |
| clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT05050097 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma(MonumenTAL-2) | active not recruiting | Phase 1 | 166 | Janssen Research & Development, LLCINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT06425991 | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-10) | active not recruiting | Phase 1 | 108 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | active not recruiting | Phase 1 | 290 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT06604715 | A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 17 | Janssen Research & Development, LLCINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07336472 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 360 | Fortvita Biologics (USA)Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 190 | ModernaTX, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | not yet recruiting | Phase 1 | 108 | Canadian Myeloma Research GroupOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07809594 | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma(GZLTCST0001) | active not recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03672318 | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04879043 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 78 | Heidelberg Pharma AGINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | active not recruiting | Phase 1 | 100 | PfizerINDUSTRY | 3 | Sep 15, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07342114 | A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats With With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 240 | Genentech, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma(PLYCOM) | recruiting | Phase 1 / Phase 2 | 200 | Hoffmann-La RocheINDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT05927571 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 | 120 | Genentech, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07601100 | Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma(IsaIberVD) | not yet recruiting | Phase 1 / Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06523699 | Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant | active not recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 62 | Natalie CallanderOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06375044 | Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT06934044 | A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07075185 | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma(inMMyCAR) | recruiting | Phase 1 | 70 | Kelonia Therapeutics, Inc.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03271632 | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05836896 | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies(CARLOTTA01) | recruiting | Phase 1 | 16 | Technische Universität DresdenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06429150 | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06006741 | Universal CAR-T Cells Targeting Multiple Myeloma | not yet recruiting | Phase 1 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01297764 | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(QUAD) | active not recruiting | Phase 1 / Phase 2 | 17 | Hackensack Meridian HealthOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 18 | BrightPath Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 21, 2026 | clinicaltrials |
| NCT06066359 | Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma | recruiting | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 20 hours agoSource updated Sep 29, 2026source: clinicaltrials